A long sought change to the Medicare drug price negotiation program benefiting orphan drug developers appears more likely to move through Congress this year. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
